MYDA Advisors LLC acquired a new stake in shares of Beigene Ltd (NASDAQ:BGNE) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 4,600 shares of the company’s stock, valued at approximately $450,000.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in BGNE. Quantbot Technologies LP purchased a new stake in Beigene in the 3rd quarter worth about $160,000. Tower Research Capital LLC TRC purchased a new stake in Beigene in the 4th quarter worth about $182,000. Comerica Bank purchased a new stake in Beigene in the 4th quarter worth about $246,000. Teachers Retirement System of The State of Kentucky purchased a new stake in Beigene in the 3rd quarter worth about $248,000. Finally, Mackenzie Financial Corp purchased a new stake in Beigene in the 4th quarter worth about $250,000. 52.22% of the stock is owned by institutional investors and hedge funds.
A number of analysts recently weighed in on BGNE shares. Maxim Group set a $120.00 price objective on shares of Beigene and gave the stock a “buy” rating in a research report on Monday, December 18th. Cowen reaffirmed a “buy” rating on shares of Beigene in a research report on Tuesday, November 14th. Robert W. Baird reaffirmed a “hold” rating and set a $138.00 target price on shares of Beigene in a research report on Thursday, March 1st. ValuEngine downgraded shares of Beigene from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd. Finally, BidaskClub upgraded shares of Beigene from a “hold” rating to a “buy” rating in a research note on Friday, January 5th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $127.67.
Beigene Ltd (NASDAQ BGNE) traded down $2.30 during trading hours on Wednesday, hitting $153.18. 367,928 shares of the stock traded hands, compared to its average volume of 364,607. Beigene Ltd has a 1-year low of $34.36 and a 1-year high of $164.15. The company has a quick ratio of 6.02, a current ratio of 6.09 and a debt-to-equity ratio of 0.23. The firm has a market capitalization of $8,265.08, a P/E ratio of -63.72 and a beta of 0.58.
Beigene (NASDAQ:BGNE) last issued its earnings results on Wednesday, February 28th. The company reported ($2.19) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.79) by ($0.40). The company had revenue of $18.17 million for the quarter, compared to analysts’ expectations of $23.00 million. research analysts forecast that Beigene Ltd will post -7.69 earnings per share for the current fiscal year.
In other Beigene news, CEO John Oyler sold 20,137 shares of Beigene stock in a transaction on Tuesday, December 26th. The shares were sold at an average price of $96.46, for a total value of $1,942,415.02. Following the completion of the transaction, the chief executive officer now owns 110,179 shares of the company’s stock, valued at $10,627,866.34. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bros. Advisors Lp Baker acquired 1,980,198 shares of the business’s stock in a transaction on Thursday, January 18th. The stock was purchased at an average cost of $101.00 per share, with a total value of $199,999,998.00. The disclosure for this purchase can be found here. In the last three months, insiders have sold 164,475 shares of company stock valued at $22,963,626. 19.90% of the stock is currently owned by corporate insiders.
WARNING: This news story was originally published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://www.thelincolnianonline.com/2018/03/14/myda-advisors-llc-acquires-shares-of-4600-beigene-ltd-bgne.html.
Beigene Company Profile
BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.